[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!
Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1964 1
1965 1
1969 2
1971 1
1972 1
1978 1
1979 2
1984 1
1988 5
1989 7
1990 7
1991 7
1992 5
1993 1
1994 2
1995 4
1996 3
1997 7
1998 2
1999 1
2000 3
2001 1
2003 2
2004 1
2007 2
2008 2
2009 3
2010 6
2011 6
2012 5
2013 6
2014 11
2015 13
2016 4
2017 16
2018 16
2019 19
2020 21
2021 24
2022 15
2023 14
2024 29
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

252 results

Results by year

Filters applied: . Clear all
Page 1
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.
Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Ng S, Francis RJ, Gedye C, Rutherford NK, Weickhardt A, Scott AM, Lee ST, Kwan EM, Azad AA, Ramdave S, Redfern AD, Macdonald W, Guminski A, Hsiao E, Chua W, Lin P, Zhang AY, McJannett MM, Stockler MR, Violet JA, Williams SG, Martin AJ, Davis ID; TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Hofman MS, et al. Lancet. 2021 Feb 27;397(10276):797-804. doi: 10.1016/S0140-6736(21)00237-3. Epub 2021 Feb 11. Lancet. 2021. PMID: 33581798 Clinical Trial.
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial.
Buteau JP, Martin AJ, Emmett L, Iravani A, Sandhu S, Joshua AM, Francis RJ, Zhang AY, Scott AM, Lee ST, Azad AA, McJannett MM, Stockler MR, Williams SG, Davis ID, Hofman MS; TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Buteau JP, et al. Lancet Oncol. 2022 Nov;23(11):1389-1397. doi: 10.1016/S1470-2045(22)00605-2. Epub 2022 Oct 16. Lancet Oncol. 2022. PMID: 36261050 Clinical Trial.
Guidelines on the management of abnormal liver blood tests.
Newsome PN, Cramb R, Davison SM, Dillon JF, Foulerton M, Godfrey EM, Hall R, Harrower U, Hudson M, Langford A, Mackie A, Mitchell-Thain R, Sennett K, Sheron NC, Verne J, Walmsley M, Yeoman A. Newsome PN, et al. Among authors: langford a. Gut. 2018 Jan;67(1):6-19. doi: 10.1136/gutjnl-2017-314924. Epub 2017 Nov 9. Gut. 2018. PMID: 29122851 Free PMC article.
ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
Emmett L, Subramaniam S, Joshua AM, Crumbaker M, Martin A, Zhang AY, Rana N, Langford A, Mitchell J, Yip S, Francis R, Hofman MS, Sandhu S, Azad A, Gedye C, McJannett M, Stockler MR, Davis ID; Australian, New Zealand Urogenital, Prostate Cancer Trials Group (ANZUP), the ENZA-p investigators. Emmett L, et al. Among authors: langford a. BJU Int. 2021 Nov;128(5):642-651. doi: 10.1111/bju.15491. Epub 2021 Jul 6. BJU Int. 2021. PMID: 34028967
Cancer misinformation on social media.
Loeb S, Langford AT, Bragg MA, Sherman R, Chan JM. Loeb S, et al. Among authors: langford at. CA Cancer J Clin. 2024 Sep-Oct;74(5):453-464. doi: 10.3322/caac.21857. Epub 2024 Jun 19. CA Cancer J Clin. 2024. PMID: 38896503 Free PMC article. Review.
Achieving sustainable healthcare through deprescribing.
Gnjidic D, Johansson M, Meng DM, Farrell B, Langford A, Reeve E. Gnjidic D, et al. Among authors: langford a. Cochrane Database Syst Rev. 2022 Oct 4;10(10):ED000159. doi: 10.1002/14651858.ED000159. Cochrane Database Syst Rev. 2022. PMID: 36194519 Free PMC article. No abstract available.
What do clinical practice guidelines say about deprescribing? A scoping review.
Langford AV, Warriach I, McEvoy AM, Karaim E, Chand S, Turner JP, Thompson W, Farrell BJ, Pollock D, Moriarty F, Gnjidic D, Ailabouni NJ, Reeve E. Langford AV, et al. BMJ Qual Saf. 2024 Dec 13;34(1):28-39. doi: 10.1136/bmjqs-2024-017101. BMJ Qual Saf. 2024. PMID: 38789258 Free PMC article. Review.
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial.
Emmett L, Subramaniam S, Crumbaker M, Nguyen A, Joshua AM, Weickhardt A, Lee ST, Ng S, Francis RJ, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Gedye C, Rutherford NK, Sandhu S, Kumar AR, Pook D, Ramdave S, Nadebaum DP, Voskoboynik M, Redfern AD, Macdonald W, Krieger L, Schembri G, Chua W, Lin P, Horvath L, Bastick P, Butler P, Zhang AY, Yip S, Thomas H, Langford A, Hofman MS, McJannett M, Martin AJ, Stockler MR, Davis ID; ENZA-p Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Emmett L, et al. Among authors: langford a. Lancet Oncol. 2024 May;25(5):563-571. doi: 10.1016/S1470-2045(24)00135-9. Epub 2024 Apr 12. Lancet Oncol. 2024. PMID: 38621400 Clinical Trial.
Shared decision-making before prostate cancer screening decisions.
Pekala KR, Shill DK, Austria M, Langford AT, Loeb S, Carlsson SV. Pekala KR, et al. Among authors: langford at. Nat Rev Urol. 2024 Jun;21(6):329-338. doi: 10.1038/s41585-023-00840-0. Epub 2024 Jan 2. Nat Rev Urol. 2024. PMID: 38168921 Review.
252 results